RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+0.23%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.56B
AUM Growth
+$7.56B
(-3.8%)
Cap. Flow
+$595M
Cap. Flow
% of AUM
7.87%
Top 10 Holdings %
Top 10 Hldgs %
53.85%
Holding
87
New
11
Increased
24
Reduced
6
Closed
9
Top Buys
| 1 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$130M |
| 2 |
Recursion Pharmaceuticals
RXRX
|
$115M |
| 3 |
Arcellx
ACLX
|
$88.5M |
| 4 |
Avidity Biosciences
RNA
|
$86.5M |
| 5 |
Biogen
BIIB
|
$56M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$91.9M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$54.6M |
| 3 |
Cytek Biosciences
CTKB
|
$45.7M |
| 4 |
VXRT
Vaxart
VXRT
|
$20M |
| 5 |
EyePoint Pharmaceuticals
EYPT
|
$19.4M |
Sector Composition
| 1 | Healthcare | 99.86% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
C4 Therapeutics
CCCC
$182M
| $22.5M | 0.3% |
4,878,000
| – | – |
|
52
Alto Neuroscience
ANRO
$97.7M
| $22.3M | 0.29% |
2,085,554
+700,063
| +51% | +$7.48M |
|
53
Immatics
IMTX
$662M
| $20.3M | 0.27% |
1,750,000
| – | – |
|
54
Sera Prognostics
SERA
$129M
| $18M | 0.24% |
3,032,808
+1,008,587
| +50% | +$5.97M |
|
|
JBIO
55
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $15.3M | 0.2% |
262,631
+26,517
| +11% | +$1.54M |
|
56
Werewolf Therapeutics
HOWL
$62.6M
| $15M | 0.2% |
6,144,881
| – | – |
|
57
CervoMed
CRVO
$93M
| $14M | 0.19% |
817,120
-44,453
| -5% | -$761K |
|
58
Pliant Therapeutics
PLRX
$105M
| $13.8M | 0.18% |
1,281,000
| – | – |
|
59
Nurix Therapeutics
NRIX
$723M
| $13.6M | 0.18% |
+650,000
| New | +$13.6M |
|
60
Insmed
INSM
$30.3B
| $13.4M | 0.18% |
+200,000
| New | +$13.4M |
|
61
AN2 Therapeutics
ANTX
$35.3M
| $11.9M | 0.16% |
5,551,295
| – | – |
|
|
CYBN
62
Cybin
CYBN
$142M
| $11.9M | 0.16% |
1,158,012
-371,976
| -24% | -$3.83M |
|
63
Zura Bio
ZURA
$132M
| $11.3M | 0.15% |
+3,217,503
| New | +$11.3M |
|
64
Arvinas
ARVN
$580M
| $11.2M | 0.15% |
421,348
| – | – |
|
|
RGLS
65
DELISTED
Regulus Therapeutics
RGLS
| $11.2M | 0.15% |
6,250,000
| – | – |
|
66
Lexeo Therapeutics
LXEO
$266M
| $10.8M | 0.14% |
672,712
+11,774
| +2% | +$189K |
|
67
Adicet Bio
ACET
$60.8M
| $9.12M | 0.12% |
7,541,000
| – | – |
|
68
Nuvalent
NUVL
$5.74B
| $9.09M | 0.12% |
+119,789
| New | +$9.09M |
|
69
MacroGenics
MGNX
$121M
| $8.85M | 0.12% |
2,082,021
| – | – |
|
|
BOLD
70
Boundless Bio
BOLD
$25.7M
| $8.44M | 0.11% |
2,180,631
| – | – |
|
|
CMRX
71
DELISTED
Chimerix, Inc.
CMRX
| $7.71M | 0.1% |
8,800,000
| – | – |
|
|
PCSC
72
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.55M | 0.1% |
+750,000
| New | +$7.55M |
|
73
Metagenomi
MGX
$67.2M
| $6.03M | 0.08% |
1,477,749
-266,666
| -15% | -$1.09M |
|
74
Protara Therapeutics
TARA
$125M
| $3.95M | 0.05% |
+1,900,000
| New | +$3.95M |
|
75
Surrozen
SRZN
$107M
| $3.09M | 0.04% |
+282,580
| New | +$3.09M |
|